Clinical Trial Update: Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial compares lenvatinib plus everolimus versus cabozantinib for second- or third-line treatment of metastatic clear cell renal cell carc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Afinitor (everolimus)
• Cabometyx (cabozantinib)
• LENVIMA (lenvatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING